Aug. 29 Company Quick Takes: EC approves Tecentriq for breast cancer, Giapreza for hypotension; plus Innovent reports Tyvyt sales

EC approves Tecentriq for breast cancer
The European Commission approved Tecentriq atezolizumab from Roche (SIX:ROG; OTCQX:RHHBY) in combination

Read the full 163 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE